CPSF6 is altered in 0.14% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, conventional glioblastoma multiforme, dysembryoplastic neuroepithelial tumor, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CPSF6 are CPSF6-FGFR1 Fusion (0.22%), CPSF6-GLI1 Fusion (0.01%), and CPSF6-MET Fusion (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.